Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended September 30, 2021

 Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2021. The said meeting of the Board commenced at 5.30 p.m. and concluded at 9.40 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release, Investor Presentation and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com You are requested to take the same on record.
12-11-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Enclosed please find herewith the details of- Earnings Call slated for Monday, November 15, 2021 at 8:30 a.m. - 9:30 a.m. (1ST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.
03-11-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window

 We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, November 12, 2021, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2021. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2021 to November 14, 2021 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2021.
01-11-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2021

 GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 ,inter alia, to consider and approve Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2021
01-11-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India
26-10-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholding for the Period Ended September 30, 2021

 Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here
19-10-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2021

 This is to certify that all activities in relation to both physical and electronic share transfer facilities are maintained by Registrar to an issue and Share Transfer Agent 'M/s. KFin Technologies Private Limited' registered with Securities Exchange Board of India under Registration Number INR000000221. Please take the same on records.
14-10-2021
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Statement Of Investor Complaints For The Quarter Ended September 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- Mr Harish KuberDesignation :- Company Secretary and Compliance Officer
13-10-2021

Glenmark Pharma launches Tavulus for COPD treatment in Spain

 COPD is a long-term condition that causes inflammation in the lungs, damaging the lung tissue and narrowing the airways, all of which make breathing difficult. Glenmark will sell the powder under the brand name Tavulus.
11-10-2021
Bigul

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark launches Tavulus(r) for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler
11-10-2021
Next Page
Close

Let's Open Free Demat Account